Maximizers are affecting patients faster than before, with >50% reaching benefit limits in 9 months or less in 2022. This trend is most pronounced in oncology, where 38% of patients hit limits in under 6 months. While many manufacturers provide additional forms of support beyond copay cards to ensure patient stability, the coverage might not always be enough to offset the impact. via IQVIA report https://bit.ly/3YFLm2V
This is indeed very interesting from a patient’s perspective. When you view it from a lens such as PMPM, the impact of current C> products is modest. This too will, however, move up aggressively when we move to C> 2.0 - new C> platforms and C>s moving away from orphan diseases
New Economics & Market Access Lead, Life Sciences Strategy
1ySuch an important call out, Audrey--the acceleration shown here is wild. The average launch price for new therapies hit ~$180k in 2021...that's somewhat skewed due to C> launches, but together with the above makes plain how real this challenge is for patients trying to get access to their medicines.